Renal & Urology News

Researchers Question Credibility of Subgroup Analyses in Cancer Trials

Claims of differential treatment effects were largely rated as “low credibility” or “very low credibility.” Subgroup analyses in cancer trials may not be credible, and their results should be ...
The American Journal of Managed Care

There Is No Interaction Between BMI and SGLT2 Inhibitor Efficacy in HF, Review Finds

Among patients with heart failure (HF), those taking dapaglifozin or empaglifozin had a 30% odds reduction in HF hospitalization, 14% odds reduction in cardiovascular mortality, and a 10% odds ...
The American Journal of Managed Care

Key Takeaways From CEPHEUS: Subgroup Analysis

Panelists discuss how emerging evidence from first-line therapy trials continues to demonstrate the superiority of quadruplet over triplet regimens, with the CEPHEUS subgroup analysis confirming that ...
TCTMD

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Two new analyses of the FINEARTS-HF trial may help physicians decide how, and for whom, finerenone can best be used to treat heart failure with mildly reduced or preserved ejection fraction ...
Business Wire

New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse cardiovascular events across various patient groups

These subgroup analyses add to the existing evidence of bempedoic acid as an effective treatment for the reduction of cardiovascular risk. MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe GmbH ...